|
CSIR-IICT and PI Industries ink pact for transfer of process technology to manufacture Covid drug 2-DG
|
|
Our Bureau, Hyderabad
July 10 , 2021
|
|
|
The Hyderabad-based CSIR-Indian Institute of Chemical Technology (CSIR-IICT) and PI Industries limited have signed an agreement to transfer process technology for the manufacture of Covid drug 2-DG.
According to Dr Chandrasekhar, director of CSIR-IICT, in line with CSIR’s efforts to help people get access to various therapeutic options to combat Covid-19, they have decided to transfer process technology to PI Industries and accordingly an agreement has been signed.
As it is known that earlier the Defense Research Development Organization (DRDO) had developed the 2-DG medicine, which had shown promising cure for severely infected Covid patients and already the Drugs Controller General of India (DCGI) has cleared the formulation on May 1 for emergency use as an adjunct therapy in moderate to severe Covid-19 patients.
However, further studies carried out by lead institutes like CSIR-IICT had shown promising results for 2-DG anti-Covid oral drug that demonstrated quick recovery and reduction in oxygen dependence among moderately and severely affected patients. This drug which is in the form of powder formulation was earlier launched by Dr. Reddy’s Laboratories in India.
As the clinical trials have shown promising results for 2-DG drug against Covid disease, the CSIR-IICT now wants this drug to be more accessible to the public. In view of this, the public sector institution is signing license agreement with as many firms as possible for its manufacture. As part of this, under the terms of the license agreement, PI Industries will be getting license for the process knowhow for synthesis of 2-DG (2-deoxy-D-glucose).
“The CSIR-IICT has been signing license agreements with various firms and pharma manufacturing companies. The main objective of this is to make sure that the public gets access to affordable Covid drug on time. In pursuance to invent, discover and develop apt drug to counter Covid disease scientists at CSIR-IICT and various other lead research instructions are undertaking clinical trials on various repurposed drugs. Very soon we may come up with many more medicines to combat the Covid disease,” informed the IICT director.
At present, PI Industries is in the process of filing the application for getting the approval from DCGI at New Delhi and will subsequently manufacture and commercialize 2-DG from their facilities.
|
|
|
|
|
|
|
|
TOPICS
|
Shanghai-based Hualian Pharmaceutical Machinery Company Limited, a family-run enterprise with roots going back to 1986, ...
|
|
|
|
|